An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Genentech, Inc.
- Study ID
- NCT02589717
- Status
- Approved For Marketing
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Atezolizumab [TECENTRIQ] — DRUGAtezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
Study Details
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.
Key Dates
- Start date
- Nov 30, 2015
- Status verified
- Nov 2016
- Primary completion
- Aug 31, 2016
- Completion
- Aug 31, 2016
Locations (40)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Scottsdale | Arizona | 85258 | - |
| - | Tucson | Arizona | 85710 | - |
| - | Duarte | California | 91010 | - |
| - | Oakland | California | 94611 | - |
| - | Stanford | California | 94305 | - |
| - | Denver | Colorado | 80218 | - |
| - | New Haven | Connecticut | 06520 | - |
| - | West Hartford | Connecticut | 06119 | - |
| - | Miami Beach | Florida | 33140 | - |
| - | Tampa | Florida | 33612 | - |
| - | Harvey | Illinois | 60426 | - |
| - | Springfield | Illinois | 62794-9677 | - |
| - | Goshen | Indiana | 46526 | - |
| - | Indianapolis | Indiana | 46237 | - |
| - | Sioux City | Iowa | 51101 | - |
| - | Louisville | Kentucky | 40202 | - |
| - | New Orleans | Louisiana | 70112 | - |
| - | Boston | Massachusetts | 02114 | - |
| - | Boston | Massachusetts | 02115 | - |
| - | Boston | Massachusetts | 02215 | - |
| - | Ann Arbor | Michigan | 48106 | - |
| - | Detroit | Michigan | 48202 | - |
| - | Saint Cloud | Minnesota | 56303 | - |
| - | Jackson | Mississippi | 39202 | - |
| - | St Louis | Missouri | 63110 | - |
| - | Albuquerque | New Mexico | 87131-0001 | - |
| - | Abany | New York | 12208 | - |
| - | New York | New York | 10016 | - |
| - | Rochester | New York | 14642 | - |
| - | Columbus | Ohio | 43210 | - |
| - | Eugene | Oregon | 97401-8122 | - |
| - | Easton | Pennsylvania | 18045 | - |
| - | Philadelphia | Pennsylvania | 19107 | - |
| - | Pittsburgh | Pennsylvania | 15212 | - |
| - | Charleston | South Carolina | 29425 | - |
| - | Houston | Texas | 77030 | - |
| - | San Antonio | Texas | 78229 | - |
| - | Charlottesville | Virginia | 22908 | - |
| - | Norfolk | Virginia | 23502 | - |
| - | Spokane | Washington | 99208 | - |
Find similar trials in Scottsdale, AZ
By condition
Related Studies
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderPHASE1/PHASE2 · Recruiting · Noah Hahn, M.D. · Phoenix, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Multicenter Cancer Biospecimen Collection StudyRecruiting · Cofactor Genomics, Inc. · San Francisco, California
- An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or BiopsyRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas